Small molecule glucagon release inhibitors with activity in human islets
PurposeType 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the im...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2023-04-01
|
| Seri Bilgileri: | Frontiers in Endocrinology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1114799/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|